Position in TNGX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$57,530,000
+$35,782,581 QoQ
Shares Held
2,750,000
+12.0% QoQ
Ownership
1.90%
of shares outstanding
% of Portfolio
1.19%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in TNGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Deep Track Capital, LP holds $4,185,471,777 across 55 Biotechnology names. TNGX ranks #25 (1.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IMVT |
Immunovant, Inc.
|
11,526,971 | $286,329,959 | |
| 2 | TARS |
Tarsus Pharmaceuticals, Inc.
|
3,600,000 | $252,540,000 | |
| 3 | PCVX |
Vaxcyte, Inc.
|
4,300,000 | $249,873,000 | |
| 4 | GPCR |
Structure Therapeutics Inc.
|
4,279,848 | $206,288,673 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
1,100,000 | $185,922,000 | |
| 6 | APLS |
Apellis Pharmaceuticals, Inc.
|
4,532,374 | $182,337,406 | |
| 7 | OCUL |
Ocular Therapeutix, Inc
|
19,686,282 | $166,742,808 | |
| 8 | VERA |
Vera Therapeutics, Inc.
|
4,106,067 | $165,187,075 |
All Filings in TNGX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $57,530,000 | 2,750,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $21,747,419 | 2,454,562 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $12,218,320 | 1,454,562 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||